November 16, 2009Inflammatory Bowel Diseases112 citations
View Full PaperRandomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease
Key Points
Key points are not available for this paper at this time.
Abstract
Apilimod was well-tolerated but did not demonstrate efficacy over placebo in patients with active CD.